Skip to Content
Merck
  • Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy.

Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy.

Brain & development (2010-07-16)
Vincenzo Belcastro, Laura Pierguidi, Nicola Tambasco
ABSTRACT

Several new antiepileptic drugs (AEDs) have been introduced for clinical use recently. These new AEDs, like the classic AEDs, target multiple cellular sites both pre- and postsynaptically. The use of AEDs as a possible neuroprotective strategy in brain ischemia is receiving increasing attention and the antiepileptic drug levetiracetam, a 2S-(2-oxo-1-pyrrolidiny1) butanamide, belonging to the pyrrolidone family, could have a crucial role in regulation of epileptogenesis and neuroprotection. Recent observations suggest that levetiracetam is both safe and effective against post-stroke seizures. In this review, the potential neuroprotective role in brain ischemia and the therapeutic implications of levetiracetam in post-stroke epilepsy are discussed.

MATERIALS
Product Number
Brand
Product Description

Supelco
Levetiracetam, Pharmaceutical Secondary Standard; Certified Reference Material
Levetiracetam, European Pharmacopoeia (EP) Reference Standard
USP
Levetiracetam, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Levetiracetam, ≥98% (HPLC)